nasal spray suspension
Sponsors
Inmunotek S.L., LETI Pharma S.L.U.
Conditions
Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Dermatophagoides farinaebirch pollen-induced allergic rhinitis
birch pollen-induced allergic rhinoconjunctivitis
Phase 3
A prospective, randomized, double-blind placebo-controlled multicentre trial with mannan-conjugated birch pollen allergoids administered subcutaneously to adolescents and adults with birch pollen-induced allergic rhinitis or rhinoconjunctivitis.
CompletedCTIS2024-515717-17-00
Start: 2024-10-28End: 2025-06-27Target: 360Updated: 2025-08-07
A multicenter, double-blind, placebo-controlled, clinical trial to evaluate the efficacy and safety of two concentrations of a mixture of depigmented polymerized allergenic extracts of D. pteronyssinus and D. farinae, in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma
Not yet recruitingCTIS2025-521230-29-00
Target: 320Updated: 2025-12-05